Literature DB >> 11862169

Practical evaluation and management of cutaneous lymphoma.

Maxwell A Fung1, Michael J Murphy, Diane M Hoss, Jane M Grant-Kels.   

Abstract

UNLABELLED: Accurate evaluation of patients with suspected or known cutaneous lymphoma requires the integration of many sources and types of information, including clinical evaluation, microscopic analysis of tissue, immunophenotyping, gene rearrangement studies, clinical staging, and longitudinal observation. Diagnoses should be based on knowledge of specific lymphoma types as described in modern classification systems. Management of patients with cutaneous lymphoma requires collaboration among dermatologists, dermatopathologists, hematopathologists, and medical, surgical and radiation oncologists. (J Am Acad Dermatol 2002;46:325-57.) LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should better understand how to evaluate and manage patients for suspected or established lymphoma of the skin. Components include the clinical history and physical examination, optimal biopsy and tissue handling, interpretation of pathology and adjunctive test results, clinicopathologic correlation, and therapy. Participants should also understand the basis for establishing a specific diagnosis of cutaneous lymphoma based on current classification and staging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862169     DOI: 10.1067/mjd.2002.121355

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Pigmentation Disorders in the Elderly.

Authors:  Andrew M Armenta; Emily D Henkel; Ammar M Ahmed
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Primary cutaneous CD 30+ anaplastic large cell lymphoma.

Authors:  S Devaji Rao; R Ravi; Meera Govindarajan
Journal:  Indian J Surg       Date:  2010-10-20       Impact factor: 0.656

3.  Successful Use of the 308-nm Excimer Laser in Early Patch Stage Mycosis Fungoides.

Authors:  Andrew M Armenta; Krystal M Jones; Jason S Reichenberg
Journal:  J Lasers Med Sci       Date:  2019-07-06

4.  Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Authors:  Narin Apisarnthanarax; Gary S Wood; Seth R Stevens; Sean Carlson; Derek V Chan; Lili Liu; Sarolta K Szabo; Pingfu Fu; Anita C Gilliam; Stanton L Gerson; Scot C Remick; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2012-05

5.  Primary Cutaneous CD30-Positive Large T-Cell Lymphoma in an 80-Year-Old Man: A Case Report.

Authors:  Rehan Hussain; Amir Bajoghli
Journal:  ISRN Dermatol       Date:  2011-03-30

6.  Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature.

Authors:  Luca Guarnera; Federico Meconi; Marco Pocci; Fabiana Esposito; Manuela Rizzo; Vito Mario Rapisarda; Annagiulia Zizzari; Cosimo Di Raimondo; Livio Pupo; Lucia Anemona; Maria Cantonetti
Journal:  Hematol Rep       Date:  2022-03-23

7.  A Clinicopathological Analysis of Primary Cutaneous Lymphomas: A 6-year Observational Study at a Tertiary Care Center of South India.

Authors:  Anza Khader; Shiny Padinjarayil Manakkad; Mohammed Shaan; Sarita Sasidharan Pillai; Najeeba Riyaz; P Binitha Manikoth; Muhammed Kunnummel; Sunitha Balakrishnan
Journal:  Indian J Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.494

8.  Rare variant of mycosis fungoides.

Authors:  Iqbal A Bukhari
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

9.  Recurrent Bacterial Infections in Cutaneous T-cell Lymphoma.

Authors:  Bharadwaj Adithya Sateesh; Yash V Bhagat; Sneha E Thomas; Aseem Sood; Miriam B Michael
Journal:  Cureus       Date:  2022-01-03

Review 10.  Total skin electron irradiation techniques: a review.

Authors:  Tomasz Piotrowski; Piotr Milecki; Małgorzata Skórska; Dorota Fundowicz
Journal:  Postepy Dermatol Alergol       Date:  2013-02-20       Impact factor: 1.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.